Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
Provided By GlobeNewswire
Last update: Nov 26, 2024
Resubmission addresses questions raised in January 2024 Complete Response Letter
F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy
Read more at globenewswire.com
